Olivier DAUBRY

Regional Vice-President, South Europe, Celgene

At the end of the 1980s, biotechnology companies took the risk of investing in genetic engineering to develop the treatments of the future. Celgene’s particular history in hematology and rare diseases clearly illustrates the courage and entrepreneurial values of a biopharmaceutical company dedicated to developing new treatments intended to transform patients’ lives. Investing 30% of our turnover every year in R&D, we make high-risk investments with innovative therapeutic developments including immunomodulators, hypomethylators, HDACs, vaccines, PDE4 and kinase inhibitors, nanotechnology-based therapies, cancer cell metabolism and cellular therapies. Celgene Cellular Therapeutics division strives to establish Celgene as the preeminent biopharmaceutical company in Cellular Medicine committed to the discovery, development and marketing of novel human cellular-based therapeutic products. By harnessing the unique biological activities of placenta-derived cells, while also developing a broad and deep pipeline of proprietary cellular therapies, Celgene Cellular Therapeutics aims to revolutionize the treatment of debilitating and life-threatening diseases. In view of our culture, our mission and our history, we see it as a natural step to sponsor the ESSEC Chair of Therapeutic Innovation, supporting the training of young entrepreneurs who promote and are active in health innovation. I have the most sincere wish that this partnership will serve as a laboratory for novel ideas and thinking to support therapeutic innovations and patients.